INBRX-120, a CD8α-targeted detuned IL-2 that selectively expands and activates tumoricidal effector cells for safe and durable in vivo responses

BACKGROUND: As a major driver of lymphocyte proliferation and activation interleukin 2 (IL-2) is a crucial mediator for antitumor responses. Despite promising activity in a subset of patients, wider therapeutic utility of IL-2 (aldesleukin) has been hampered by severe dose-limiting toxicities, the e...

Descripción completa

Detalles Bibliográficos
Autores principales: Sulzmaier, Florian J, Kern, Nadja, Ahn, Sae Jeong, Polovina, Anya, Ho, Jason, Hussain, Abrahim, Cyprus, Garrett, Macedo, Chelsie, Pandit, Rajay, Crago, William, Rowell, Emily, Timmer, John C, Eckelman, Brendan P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9853254/
https://www.ncbi.nlm.nih.gov/pubmed/36653071
http://dx.doi.org/10.1136/jitc-2022-006116

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9853254/
https://www.ncbi.nlm.nih.gov/pubmed/36653071
http://dx.doi.org/10.1136/jitc-2022-006116

Ejemplares similares